TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Significant Decrease in Short Interest

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 743,600 shares, a decrease of 39.0% from the October 15th total of 1,220,000 shares. Based on an average daily trading volume, of 1,700,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 4.3% of the shares of the company are short sold.

TransCode Therapeutics Stock Down 2.9 %

RNAZ traded down $0.01 during trading on Friday, hitting $0.34. The company’s stock had a trading volume of 264,385 shares, compared to its average volume of 1,253,209. The business’s 50 day simple moving average is $0.49 and its 200-day simple moving average is $0.69. TransCode Therapeutics has a one year low of $0.22 and a one year high of $18.66.

TransCode Therapeutics (NASDAQ:RNAZ) last released its earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.16). As a group, equities analysts forecast that TransCode Therapeutics will post -2.06 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of TransCode Therapeutics in a research report on Friday.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.